4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. ( FDMT ) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:20 AM EDT Company Participants Kristian Humer - CFO and Principal Financial & Accounting Officer Christopher Simms - Chief Commercial & Business Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Cantor Fitzgerald & Co., Research Division Thanks very much. I'm Josh Schimmer from the Cantor Biotech Equity Research team. I'm very pleased to introduce from 4D Molecular Therapeutics. We have Kristian Humer, Chief Financial Officer; and Chris Simms, Chief Commercial Officer. Question-and-Answer Session Joshua Schimmer Cantor Fitzgerald & Co., Research Division Kristian, why don't we get things started? Give us a quick snapshot of where 4D is today and where the company is headed. Kristian Humer CFO and Principal Financial & Accounting Officer Perfect. First of all, thank you, Josh, for having us. Really, really appreciate it. So 4D in terms of pipeline, we have our lead program, 4D-150 is in Phase III for Wet AMD. Our two Phase III trials are fully enrolled. We're guiding to the first Phase III trial to read out in Q2 of next year and the second Phase III trial to read out in the second half of next year. We will announce towards the end of the month, the initiation of a Phase III trial in DME, the next indication for 4D-150. We have a kind of lung program in 4D-710, where we'll provide an operational update towards the end of the year. That's a program in CF. From a cash perspective, we've got around $458 million in cash as of 6/30 this year with cash runway into the second half of 2028. Joshua Schimmer Cantor Fitzgerald & Co., Research Division Okay. Excellent. So as we gear up for the 4FRONT clinical